Ensign Peak Advisors
ACRS icon

Ensign Peak Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Ensign Peak Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,950
Closed -$251K – 1789
2022
Q3 		$251K Buy
15,950
+4,980
+45% +$78.5K ﹤0.01% 1784
2022
Q2 		$153K Hold
10,970
– – ﹤0.01% 1874
2022
Q1 		$189K Hold
10,970
– – ﹤0.01% 1890
2021
Q4 		$160K Buy
+10,970
New +$166K ﹤0.01% 1973

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ensign Peak Advisors's ACRS Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 15,950 shares — an estimated $251K sold.

Ensign Peak Advisors first reported a position in ACRS in Q4 2021 and held it in 4 quarters. The position peaked at $251K in Q3 2022. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 15,950 Aclaris Therapeutics shares in Q4 2022, an estimated $251K.
  • Ensign Peak Advisors first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Aclaris Therapeutics position peaked at $251K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.